EEF1A1 and cancer: In PC-3 cells, used as a model for aggressive CRPC cancer [17], the aptamer GT75 can bind eEF1A1 in vitro, reduce cell viability, and promote cell detachment and autophagy, suggesting that eEF1A1 may be a therapeutic target for advanced prostate cancers.